clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Ergotism D004881 4 associated lipids
Ecchymosis D004438 3 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Dyspepsia D004415 5 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Giardiasis D005873 3 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Tartaglione T Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin. 1997 Jul-Aug Clin Ther pmid:9377608
Mikasa K et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. 1997 Jul-Aug Chemotherapy pmid:9209786
Nawarskas JJ et al. Digoxin toxicity secondary to clarithromycin therapy. 1997 Jul-Aug Ann Pharmacother pmid:9220047
al-Humayyd MS Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat. 1997 Mar-Apr Chemotherapy pmid:9084915
Svoboda P et al. Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. 1997 May-Jun Hepatogastroenterology pmid:9222709
Best LM et al. Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. 1997 May-Jun Can. J. Gastroenterol. pmid:9218854
O'Brien B et al. Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer. 1997 May-Jun Can. J. Gastroenterol. pmid:9218858
Guerriero SE et al. Two cases of clarithromycin-induced digoxin toxicity. 1997 Sep-Oct Pharmacotherapy pmid:9324195
Anzueto A et al. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group. 1997 Sep-Oct Clin Ther pmid:9385486
Soepandi P et al. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. 1998 Respirology pmid:9692520
van Westrhenen R et al. Pneumonia and glomerulonephritis caused by Mycoplasma pneumoniae. 1998 Nephrol. Dial. Transplant. pmid:9870493
Waddell ST et al. Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. 1998 Bioorg. Med. Chem. Lett. pmid:9871759
Lee CL et al. One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers. 1998 J. Formos. Med. Assoc. pmid:9872028
Suzuki J et al. Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer. 1998 J. Clin. Gastroenterol. pmid:9872515
Sakaki N et al. Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection. 1998 J. Clin. Gastroenterol. pmid:9872520
Yoshida Y et al. Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. 1998 Bioorg. Med. Chem. Lett. pmid:9873455
Sakurai N et al. Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. 1998 Bioorg. Med. Chem. Lett. pmid:9873510
Komori T et al. Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats. 1998 Res. Commun. Mol. Pathol. Pharmacol. pmid:9874281
Matteelli A et al. Long term treatment with clarithromycin for cryptosporidiosis and emergence of drug resistant disseminated infection due to Mycobacterium avium: case report. 1998 J Chemother pmid:9876056
Vorbach H et al. Endothelial cell compatibility of clarithromycin for intravenous use. 1998 Clin. Biochem. pmid:9876898
Miglioli PA et al. Antibacterial activity of human pleural fluid: alone and in combination with antibiotics. 1998 Int. J. Antimicrob. Agents pmid:9916908
Stack WA et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. 1998 Am. J. Gastroenterol. pmid:9772054
Adamek RJ and Bethke TD Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. 1998 Am. J. Gastroenterol. pmid:9772056
Stolte M et al. Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. 1998 Z Gastroenterol pmid:9773482
Pina M et al. Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. 1998 J. Clin. Microbiol. pmid:9774580
Hawkey CJ et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. 1998 Lancet pmid:9759744
Nelson KG et al. Results of operation in Mycobacterium avium-intracellulare lung disease. 1998 Ann. Thorac. Surg. pmid:9725364
Sung JJ et al. One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9726384
Mégraud F and Doermann HP Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. 1998 Gut pmid:9764043
Pazzi P et al. Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. 1998 Aliment. Pharmacol. Ther. pmid:9726385
Heald AE et al. Taste and smell complaints in HIV-infected patients. 1998 AIDS pmid:9764787
Harris AW et al. Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. 1998 Aliment. Pharmacol. Ther. pmid:9726387
Perri F et al. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. 1998 Ital J Gastroenterol Hepatol pmid:9675647
Talley NJ et al. Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9678811
Bermudez LE et al. Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice. 1998 J. Infect. Dis. pmid:9728568
Ricciardiello L et al. Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. 1998 Aliment. Pharmacol. Ther. pmid:9678812
Gorski JC et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. 1998 Clin. Pharmacol. Ther. pmid:9728893
Cammarota G et al. One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. 1998 Aliment. Pharmacol. Ther. pmid:9678813
Barzilai A et al. Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. 1998 Scand. J. Infect. Dis. pmid:9730300
Louw JA et al. Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. 1998 Aliment. Pharmacol. Ther. pmid:9678814
Ahuja V et al. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. 1998 Aliment. Pharmacol. Ther. pmid:9678815
Grübel P and Cave DR Factors affecting solubility and penetration of clarithromycin through gastric mucus. 1998 Aliment. Pharmacol. Ther. pmid:9678818
Sax L Bacterial pharyngitis in children. 1998 J Fam Pract pmid:9451356
Igea JM and Lázaro M Hypersensitivity reaction to clarithromycin. 1998 Allergy pmid:9491242
Hermon-Taylor J et al. Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease. 1998 BMJ pmid:9492675
Bocheńska-Marciniak M et al. [Clinical efficacy and safety of spiramycin and clarithromycin in the treatment of outpatients with lower respiratory tract infections]. 1998 Pol. Arch. Med. Wewn. pmid:10335027
Aberg JA et al. Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. 1998 J. Infect. Dis. pmid:9780266
González Carro P et al. [Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori]. 1998 Rev Esp Enferm Dig pmid:9780793
Gangadharam PR Clarithromycin for non-mycobacterial diseases? 1998 Int. J. Tuberc. Lung Dis. pmid:9783536
Sakamoto M et al. [Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer]. 1998 Gan To Kagaku Ryoho pmid:9881083
Komori T et al. Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats. 1998 Biol. Pharm. Bull. pmid:9881659
Shafran SD et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. 1998 J. Infect. Dis. pmid:9419201
Martín Mir ML et al. [Effectiveness of the eradication of Helicobacter pylori by treatment with omeprazol, amoxicillin, and clarithromycin according to dosage and administration schedule]. 1998 Gastroenterol Hepatol pmid:9882932
van Aarem A et al. Recurrent therapy resistant mastoiditis by Mycobacterium cheilonae abscessus, a nontuberculous mycobacterium. 1998 Int. J. Pediatr. Otorhinolaryngol. pmid:9596371
Gisbert JP et al. [Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?]. 1998 Med Clin (Barc) pmid:9887438
Koster F Paradoxical local response to therapy for Mycobacterium avium complex infection in four patients with AIDS. 1998 Clin. Infect. Dis. pmid:9597260
Carnicer J [Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?]. 1998 Gastroenterol Hepatol pmid:9549199
Iwata M et al. [Three cases of Fitz-Hugh-Curtis syndrome detected in the early stage by abdominal ultrasonography]. 1998 Nippon Naika Gakkai Zasshi pmid:9549331
Rosina P et al. Fixed drug eruption from clarithromycin. 1998 Contact Derm. pmid:9506224
Carlson LD et al. Standardized BACTEC method to measure clarithromycin susceptibility of Mycobacterium genavense. 1998 J. Clin. Microbiol. pmid:9508306
Sato K et al. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. 1998 J. Antimicrob. Chemother. pmid:9511040
Champney WS and Burdine R Macrolide antibiotic inhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells. 1998 Microb. Drug Resist. pmid:9818968
Alegre Herrera S et al. [Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia]. 1998 An Med Interna pmid:9522506
Berquist WE New, improved Helicobacter pylori eradication therapy in children. 1998 J. Pediatr. Gastroenterol. Nutr. pmid:9523877
Collins LA et al. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. 1998 Antimicrob. Agents Chemother. pmid:9527783
Gisbert JP et al. [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. 1998 Med Clin (Barc) pmid:9527978
Hua J et al. Characterization of clinical isolates of Helicobacter pylori in Singapore. 1998 Microbios pmid:9785486
Clark CL et al. Antipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies. 1998 J. Clin. Microbiol. pmid:9817876
Björkholm B et al. Rapid PCR detection of Helicobacter pylori-associated virulence and resistance genes directly from gastric biopsy material. 1998 J. Clin. Microbiol. pmid:9817898
Arimori K et al. Characteristic difference in gastrointestinal excretion of clarithromycin and roxithromycin. 1998 Biopharm Drug Dispos pmid:9818709
Sanfélix Genovés J et al. [Helicobacter pylori: 6-day triple therapy in duodenal ulcer]. 1998 Aten Primaria pmid:9670578
Cirioni O et al. In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii. 1998 J. Antimicrob. Chemother. pmid:9818742
de Boer WA et al. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. 1998 Am. J. Gastroenterol. pmid:9672338
Vrioni G et al. Treatment of disseminated Mycobacterium genavense infection in a murine model with ciprofloxacin, amikacin, ethambutol, clarithromycin and rifabutin. 1998 J. Antimicrob. Chemother. pmid:9818747
Martin SJ and Pendland SL Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila. 1998 J. Antimicrob. Chemother. pmid:9687103
Portaels F et al. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9687409
Bigard MA et al. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. 1998 Aliment. Pharmacol. Ther. pmid:9690730
Pontani D et al. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. 1998 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9758284
Bardhan KD et al. Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. 1998 Aliment. Pharmacol. Ther. pmid:9692693
Fattorini L et al. Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. 1998 Antimicrob. Agents Chemother. pmid:9517960
Trivedi S et al. Clarithromycin and digoxin toxicity. 1998 Ann. Intern. Med. pmid:9518419
Laine L and Fendrick AM Helicobacter pylori and peptic ulcer disease. Bridging the gap between knowledge and treatment. 1998 Postgrad Med pmid:9519040
Howden CW and Hunt RH Treating Helicobacter pylori. 1998 Arch. Intern. Med. pmid:9827792
Apseloff G et al. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. 1998 J Clin Pharmacol pmid:9753212
Domingo D et al. High frequency of mutations at position 2144 of the 23S rRNA gene in clarithromycin-resistant Helicobacter pylori strains isolated in Spain. 1998 J. Antimicrob. Chemother. pmid:9630414
Fireman Z et al. Helicobacter pylori and peptic ulcer disease therapies: a survey of gastroenterologists in Israel. 1998 Helicobacter pmid:9631306
Battaglia G et al. Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules. 1998 Helicobacter pmid:9631310
Miwa H et al. Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. 1998 Helicobacter pmid:9631313
Calvet Calvo X [Treatment of Helicobacter pylori infections]. 1998 Gastroenterol Hepatol pmid:9633184
Bayoumi AM and Redelmeier DA Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. 1998 AIDS pmid:9727572
Wang G et al. Genotypic characterization of clarithromycin-resistant and -susceptible Helicobacter pylori strains from the same patient demonstrates existence of two unrelated isolates. 1998 J. Clin. Microbiol. pmid:9705423
van der Wouden EJ et al. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. 1998 Am. J. Gastroenterol. pmid:9707042
Burman WJ et al. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. 1998 AIDS pmid:9708410
Bergmann JS and Woods GL In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. 1998 Int. J. Tuberc. Lung Dis. pmid:9712275
Alder JD et al. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. 1998 Antimicrob. Agents Chemother. pmid:9736568
Améndola R et al. [Is dental plaque a normal Helicobacter pylori reservoir?]. 1998 Acta Gastroenterol. Latinoam. pmid:9713656
Takizawa H et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. 1998 Eur. Respir. J. pmid:9701415
Ward TT et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. 1998 Clin. Infect. Dis. pmid:9827282
Greenblatt DJ et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. 1998 Clin. Pharmacol. Ther. pmid:9757151
Piccolomini R et al. Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans. 1998 Antimicrob. Agents Chemother. pmid:9797240